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Biosurfactants have been the subject of an impressive amount of research efforts, both by academia as by 
the industry. Two major factors that have been limiting real commercialization of biosurfactants in the past 
are firstly the limited structural variety and secondly the high production price due to low inherent 
productivities, small scale and/or a lack of process knowledge. 
 
A solution can be offered by an integrated process design (IPD) approach, where the entire innovation 
chain is taken into account. Genetic engineering on one side of the spectrum generates new strains, which 
are subsequently subjected to thorough investigation of the production processes, with feedback coupling 
to the strain level. Subsequent scale up on one hand enables assessing the scalability of the processes and 
performing techno-economical and LCA analyses, but on the other hand also results in the generation of 
kg scale biosurfactant samples of high purity. The availability of such large amounts of a portfolio of 
molecules enables thorough application research of the new molecules and their derivatives in a vast variety 
of sectors. 
This approach has been applied for one of the showcases of biosurfactant production: the yeast Starmerella 
bombicola. The development of a molecular toolbox enabled the generation of several new S. bombicola 
strains, efficiently producing new-to-nature biosurfactants. These new strains were subjected to an iterative 
optimization process, while the production processes (fermentation and purification) for each new 
biomolecule/strain were investigated in parallel. Dedicated application research identified possible 
valorization options and a business case for the commercialization was recently finalized. The combination 
of these efforts is expected to result in real market penetration of these molecules in the near future.  
